Fluorescein lisicol

DB12030InvestigationalSmall molecule

Fluorescein lisicol has been used in trials studying the diagnostic of Pharmacokinetics, Hepatic Cirrhosis, Hepatitis, Viral, Human, Nonalcoholic Steatohepatitis, and Non-Alcoholic Fatty Liver Disease.

Formula / weight: C₅₁H₆₅N₃O₁₁S · 928.15 g/mol (avg)
Code names: NRL-972

Resolves to

Compound

UNIIU7GBB0934JCAS140616-46-2PubChem76958588

Structure

InChIKeyPVZRIVQDZVBHOW-TZCNZRNCSA-NSMILES

C[C@H](CCC(=O)N[C@@H](CCCCNC(=S)NC1=CC=C(C2C3=CC=C(O)C=C3OC3=C2C=CC(O)=C3)C(=C1)C(O)=O)C(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C

What you can answer from here — as of February 21, 2021

6Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Fluorescein lisicol, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account